Reduced radiation exposure and virus transmission is possible for both patients and providers.
When imaging children, radiation exposure is always a paramount concern. That worry remains real even during the COVID-19 pandemic. Consequently, new research pointing to the potential of using point-of-care lung ultrasound could be good news.
According to an article published on April 23 in Pediatrics, investigators from the Regina Margherita Children’s Hospital in Turin, Italy, determined lung ultrasound is an acceptable strategy for finding lung abnormalities in children with both mild and severe COVID-19 infections.
To date, only chest CT and chest X-ray have been examined in children, the team said, but lung ultrasound is a promising option.
“While the number of patients analyzed is small, the high concordance between radiologic and lung ultrasound findings suggests that ultrasound may be a reasonable method to detect lung abnormalities in children with COVID-19,” the authors wrote.
Based on World Health Organization statistics, children account for only 5 percent of infected patients. Consequently, the number of children available for assessment and analysis is low. The in the study, the team evaluated eight children ages 0 to 17 who were admitted to the hospital. Two had severe disease, two had moderate disease, and four were classified with mild disease.
Related Content: Children Experience Milder COVID-19 Cases
Within the lung ultrasound images, the team looked for signs of viral pneumonia as small subpleural consolidations and individual B-lines or confluent B-lines. The images found subpleural consolidations in two children and confluent B-lines in five. In seven cases, they found a concordance with radiologic findings, and an interstitial B-lines pattern was seen in one patient despite a normal chest X-ray.
Given these findings, the team pointed to several benefits of using lung ultrasound in children with COVID-19:
These results point to a need for more studies analyzing the use and efficacy of lung ultrasound in children with COVID-19 infection, the researchers said.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.